Clinical trials: Cell- and Tissue-Based Therapy
High-risk Neuroblastoma, Neuroblastoma
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
- Conditions
- High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma
- Trial name
- NCT06528496
- Testing
- DANYELZA, Sargramostim, Cytoxan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
RBL001/RBL002 Phase I Clinical Trial
Clinical first-in-human dose escalation study evaluating the safety and tolerability of intranodal administration of an RNA-based cancer vaccine targeting two tumor-associated antigens in patients with advanced melanoma
- Trial name
- MERIT (NCT01684241)
- Testing
- RBL001/RBL002
- Where
- 4 sites in Austria, Germany
- Volunteers
- 29 people
- Sponsor
- BioNTech RNA Pharmaceuticals GmbH
Melanoma, Neoplasm Metastasis
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase.
- Trial name
- NCT00055562
- Testing
- CC 5013
- Where
- 31 sites in United States, Canada
- Volunteers
- 274 people
- Sponsor
- Celgene Corporation
Advanced Melanoma, Recurrent Melanoma
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma.
- Conditions
- Advanced Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7
- Trial name
- NCT02965716
- Testing
- Pembrolizumab, Talimogene Laherparepvec
- Where
- 20 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
TRAQinform Assessment of Immunotherapy Response
The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study.
- Trial name
- AIQ TRAQinform (NCT05819255)
- Testing
- Non-Interventional
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- AIQ Solutions
Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
This is a Phase 1/2, open-label, dose-exploration, combination/expansion study, which will start by evaluating the safety and tolerability of NTX-301, an oral DNMT1 inhibitor, as a monotherapy in patients with advanced solid…
- Conditions
- Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma, High-grade Glioma
- Trial name
- NCT04851834
- Testing
- NTX-301, Platinum-based Chemotherapy, Temozolomide
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Xennials Therapeutics Australia Pty Ltd
Pathological Conditions, Signs and Symptoms
PTC Guiding Neoadjuvant Treatment in Breast Cancer
Patients with breast cancer meet criteria for enrollment are randomized into PTC group or control group. The neoadjuvant therapy regimens are guided by PTC test in the PTC group.
- Trial name
- NCT05103293
- Testing
- patient-derived tumor-like cell clusters drug sensitivity test
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Zhejiang Cancer Hospital
Esthesioneuroblastoma, Olfactory
Esthesioneuroblastoma: Outcomes After Treatment
The purpose of this study is to collect and organize data into a repository to gather relevant information for future research from patients diagnosed with a rare malignant sinonasal cancer called esthesioneuroblastoma (ENB) and…
- Trial name
- ENB (NCT02580136)
- Where
- United States
- Sponsor
- Ricardo L. Carrau, MD
Melanoma
Biomarker-driven Therapy for Melanoma
Patients included will undergo biopsy and the molecular analysis will be discussed at the institutional molecular tumor board. The recommandation of the molecular tumor board will be provided to the physician in charge of the…
- Trial name
- TREAT20plus (NCT05063058)
- Testing
- Molecular guided therapy
- Volunteers
- 100 people
- Sponsor
- Charite University, Berlin, Germany
Melanoma
T-cell Based Immunotherapy for of Melanoma
The aim of this study is to investigate the toxicity and clinical response of therapy with tumor infiltrating lymphocytes as treatment for advanced melanoma.
- Trial name
- NCT00937625
- Testing
- cyclophosphamide, fludarabine, T-cells, Interleukin-2
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- Inge Marie Svane
Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
This clinical trial studies genetically modified peripheral blood stem cell transplant in treating patients with HIV-associated non-Hodgkin or Hodgkin lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT01769911
- Testing
- carmustine, cytarabine, melphalan
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Brain and Central Nervous System Tumors
Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00897663
- Testing
- gene expression analysis, microarray analysis, protein expression analysis
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Clear Cell Sarcoma of the Kidney, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor
This research study is studying biomarkers in tissue samples from patients with high-risk Wilms tumor. Studying samples of tissue from patients with cancer in the laboratory may help doctors to learn more about changes that occur…
- Conditions
- Clear Cell Sarcoma of the Kidney, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Rhabdoid Tumor of the Kidney, Stage I Wilms Tumor
- Trial name
- NCT01118078
- Testing
- DNA methylation analysis, gene expression analysis, microarray analysis
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Children's Oncology Group
Non Small Cell Lung Cancer, Microbiome
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
The goal of the project is to develop and validate the BioForte technology. Its main functionality should be to in silico determine candidates for novel microbiome-based therapeutics and diagnostics.
- Conditions
- Non Small Cell Lung Cancer, Microbiome, Metagenome, Immunotherapy
- Trial name
- NCT04136470
- Testing
- Collection of stool, blood (PBMC) and biopsy (FFPE)
- Where
- 10 sites in Poland
- Volunteers
- 130 people
- Sponsor
- Ardigen
Advanced Melanoma
Dendritic Cell Based Therapy of Malignant Melanoma
The aim of the study is to show if vaccination with autologous dendritic cells pulsed with peptides or tumor lysate in combination with adjuvant cytokines and Cyclophosphamide can induce a measurable immune response in patients…
- Trial name
- NCT00197912
- Testing
- tumor antigen loaded autologous dendritic cells
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Herlev Hospital
Glioblastoma Multiforme
A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients
It is the primary objective of this study to show safety and tolerability for administration of the cell based immunotherapy ALECSAT to patients with Glioblastoma brain cancer.
- Trial name
- ALECSAT-GBM (NCT01588769)
- Testing
- ALECSAT cell based immunotherapy
- Where
- Denmark
- Volunteers
- 23 people
- Sponsor
- CytoVac A/S
Rheumatoid Arthritis
Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification
The main aim of the study is to determine the clinical utility of naive T-cell stratification for rationalising treatment with methotrexate (MTX), for DMARD-naive early RA patients.
- Trial name
- TEEMS (NCT03813771)
- Testing
- Benepali, Sulfasalazine, Methotrexate
- Where
- United Kingdom
- Volunteers
- 106 people
- Sponsor
- University of Leeds
Chronic Kidney Diseases
SVF (Adipose Tissue Derived MSC) Based Therapy for CKD.
1. To assess the safety of stromal vascular fraction (Autologous Non-Expanded ADSC) injection in patients with Chronic Kidney Disease (CKD). 2.
- Trial name
- StemCell&CKD (NCT03939741)
- Testing
- SVF Containg Autologous Non Expanded ADSC
- Where
- Bangladesh
- Volunteers
- 31 people
- Sponsor
- Bangladesh Laser & Cell Surgery Institute & Hospital
HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IIIA Breast Cancer
- Trial name
- NCT00436254
- Testing
- pNGVL3-hICD vaccine, sargramostim, flow cytometry
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Washington
Melanoma
Novel Adjuvants for Peptide-Based Melanoma Vaccines
This is a study to determine the efficacy of a melanoma vaccine chemotherapy cocktail composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in…
- Trial name
- NCT00028431
- Testing
- MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California